Investors interested in Large Cap Pharmaceuticals stocks are likely familiar with Pfizer (PFE) and Eli Lilly (LLY) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The Zacks Rank is a proven strategy that targets companies with positive earnings est ...

Core Viewpoint - Pfizer is expected to report quarterly earnings of $0.64 per share, reflecting a 22% decline year-over-year, with revenues projected at $13.88 billion, a decrease of 6.7% compared to the previous year [1]. Earnings Estimates - Analysts have not revised the consensus EPS estimate for the quarter in the past 30 days, indicating a stable outlook among analysts [1]. - Changes in earnings estimates are crucial for predicting investor reactions to the stock [2]. Revenue Projections - Analysts estimate 'Revenues- Oncology- Ibrance- Worldwide' at $898.97 million, down 14.7% from the prior year [4]. - 'Revenue- Specialty Care- Cibinqo' is projected to reach $71.20 million, an increase of 69.5% year-over-year [4]. - 'Revenues- Specialty Care- Xeljanz- Worldwide' is expected to be $141.92 million, down 26.9% from the previous year [5]. - 'Revenues- Oncology- Inlyta- Worldwide' is estimated at $207.30 million, indicating a 12.5% decline year-over-year [5]. Regional Revenue Insights - 'Revenues- Oncology- Ibrance- United States' is projected at $565.50 million, down 16.7% from the year-ago quarter [6]. - 'Revenues- Specialty Care- Xeljanz- Total International' is expected to be $101.82 million, reflecting a 15.2% decrease [6]. - 'Revenues- Oncology- Ibrance- Total International' is estimated at $333.47 million, down 11.1% year-over-year [7]. - 'Revenues- Specialty Care- Xeljanz- United States' is projected to be $40.10 million, indicating a significant decline of 45.8% [7]. Additional Revenue Metrics - 'Revenues- Oncology- Inlyta- Total International' is expected to reach $91.42 million, down 4.8% year-over-year [8]. - 'Revenues- Oncology- Inlyta- United States' is projected at $115.88 million, reflecting a 17.8% decline [8]. - 'Revenue- Primary Care- Prevnar family- United States' is estimated at $1.14 billion, a slight decrease of 0.4% from the prior year [9]. - 'Revenue- Primary Care- Prevnar family- Total International' is projected to be $550.39 million, indicating a year-over-year increase of 1.6% [9]. Stock Performance - Over the past month, Pfizer shares have returned -11.2%, compared to the Zacks S&P 500 composite's -5.1% [9]. - Pfizer currently holds a Zacks Rank 2 (Buy), suggesting potential outperformance in the near future [10].

Having significant capital in the bank when investing in equities is helpful, but is by no means necessary. Even with a relatively modest sum, like $30, it's possible to acquire one whole share of a top corporation that's likely to perform well in the long run. If you're patient and hold on to it through the kind of market volatility we're experiencing, while occasionally purchasing more shares, that should result in excellent returns.Which stocks trading for less than $30 per share are worth investing in t ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.Pfizer Inc. (NYSE: PFE ), the New York-based Pharma giant whose COVID vaccine Comirnaty earned the company >$85bn between 2021–2023, and whose COVID antiviral Paxlovid earn ...

Wall Street expects a year-over-year decline in earnings on lower revenues when Pfizer (PFE) reports results for the quarter ended March 2025. While this widely-known consensus outlook is important in gauging the company's earnings picture, a powerful factor that could impact its near-term stock price is how the actual results compare to these estimates.The stock might move higher if these key numbers top expectations in the upcoming earnings report, which is expected to be released on April 29. On the othe ...

Core Viewpoint - Pfizer (NYSE: PFE) presents a compelling investment opportunity with a high dividend yield of 7.63%, raising questions about whether this yield is sustainable or a potential trap for investors [1]. Financial Analysis - The article emphasizes the importance of financial data in assessing a company's health, suggesting that a thorough analysis of Pfizer's financials is crucial for understanding its growth prospects [1]. Investment Perspective - The author identifies as a conservative yet opportunistic value investor, indicating a cautious approach to investment while remaining open to opportunities [1].

Although it isn't the largest therapeutic area in the pharmaceutical industry, the market for weight loss therapies has caught fire in recent years. The leading medicines in this field include household names such as Wegovy and Zepbound, two drugs whose sales are rapidly growing.Their success has attracted the attention of other major drugmakers, including Pfizer (PFE 0.43%), which has been looking to dip its toes into this area. Unfortunately, recent developments make Pfizer's prospects in the weight loss ...

Pfizer Inc (NYSE: PFE ) has had a troublesome few years after the revenue boom generated by its COVID vaccine. The company was among the few beneficiaries of the need to rapidly vaccinate massive swaths of the global population, competing chieflyRetail investor researching mostly semiconductors and fintech. Some general macro musings. My goal is to bring you timely and digestible research on the stocks that I cover.Analyst’s Disclosure: I/we have a beneficial long position in the shares of PFE either throug ...

If you'd like to learn more about how to best position yourself in under valued stocks mispriced by the market to start Q1, consider joining Out Fox The Street .The vaccine fears now have Pfizer Inc. (NYSE: PFE ) trading down to only $22. The market is now pricing in major fears of lost revenues, with the dividend yield soaring to nearly 8%. MyAnalyst’s Disclosure: I/we have a beneficial long position in the shares of PFE either through stock ownership, options, or other derivatives. I wrote this article my ...

On Tuesday, investors continued to snap up shares of big pharmaceutical company Pfizer (PFE 1.51%). Somewhat counterintuitively, this week's rise came after the company announced it was ending the development of a drug in a very hot product category. On Tuesday, Pfizer's stock closed the day 1.5% higher, providing a pleasant contrast to the S&P 500 index's 0.2% dip.Weight loss drug not a lossTuesday was a relatively uneventful news day for Pfizer, especially following the pharmaceutical giant's disclosure o ...